TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Rating of “Moderate Buy” from Analysts

TG Therapeutics, Inc. (NASDAQ:TGTX) has received an average recommendation of “Moderate Buy” from the six brokerages that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $40.67.

Several equities analysts have recently commented on the stock. JPMorgan Chase & Co. boosted their target price on shares of TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research report on Monday, November 25th. StockNews.com upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday. HC Wainwright reaffirmed a “buy” rating and issued a $55.00 target price on shares of TG Therapeutics in a report on Tuesday. Finally, The Goldman Sachs Group lifted their price target on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th.

TG Therapeutics Price Performance

Shares of NASDAQ TGTX opened at $35.62 on Wednesday. The business has a fifty day moving average price of $30.86 and a two-hundred day moving average price of $28.33. The stock has a market capitalization of $5.54 billion, a PE ratio of -356.16 and a beta of 2.30. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. TG Therapeutics has a fifty-two week low of $12.93 and a fifty-two week high of $36.94.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company had revenue of $108.19 million for the quarter, compared to analysts’ expectations of $100.67 million. As a group, equities analysts predict that TG Therapeutics will post 0.08 earnings per share for the current fiscal year.

Insider Buying and Selling at TG Therapeutics

In other TG Therapeutics news, CFO Sean A. Power sold 11,337 shares of the company’s stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $30.29, for a total value of $343,397.73. Following the completion of the transaction, the chief financial officer now owns 670,632 shares of the company’s stock, valued at $20,313,443.28. This represents a 1.66 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 10.50% of the company’s stock.

Institutional Trading of TG Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Vermillion Wealth Management Inc. acquired a new stake in TG Therapeutics during the 4th quarter worth approximately $30,000. Castleark Management LLC raised its stake in shares of TG Therapeutics by 25.2% during the fourth quarter. Castleark Management LLC now owns 211,370 shares of the biopharmaceutical company’s stock valued at $6,362,000 after acquiring an additional 42,560 shares during the last quarter. Soleus Capital Management L.P. lifted its holdings in shares of TG Therapeutics by 5.8% during the fourth quarter. Soleus Capital Management L.P. now owns 2,681,242 shares of the biopharmaceutical company’s stock worth $80,705,000 after purchasing an additional 146,702 shares during the period. Wexford Capital LP acquired a new position in shares of TG Therapeutics during the fourth quarter worth $421,000. Finally, Redwood Investments LLC grew its stake in shares of TG Therapeutics by 0.9% in the fourth quarter. Redwood Investments LLC now owns 94,554 shares of the biopharmaceutical company’s stock worth $2,846,000 after purchasing an additional 886 shares during the last quarter. 58.58% of the stock is currently owned by institutional investors.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.